Search earnings tickers

ALNY

2025Q3BMO

Alnylam Pharmaceuticals Inc primary · HEALTHCARE · BIOTECHNOLOGY

Report 2025-10-30 · Fiscal end 2025-09-30 · Features as of 2025-10-29

← Earnings history

Street

Consensus EPS1.75

Consensus rev—

EPS high—

EPS low—

Dispersion—

Analysts—

EPS rev net 7d—

EPS rev net 30d—

Consensus Δ 7d—

Consensus Δ 30d—

Options

Implied move2.9%

IV front—

P/C full—

P/C front—

Features as of2025-10-29

Run-up

Close—

Ret 5d+3.6%

Ret 10d+2.4%

Ret 20d+4.5%

Ret 30d+6.6%

Print

Actual EPS

2.90Beat

Estimated EPS1.75

Actual revenue

1.2B

Surprise %+65.7%

Beat / missBeat

Beat streak 44

Beat streak 84

Reaction

1-day stock reaction-0.1%

Implied vs actual

Implied 2.9%Actual 6.6%

Gap reaction-6.6%

Day result-6.7%

Next-day upNo

Realized / IV2.25×

Post tape

Post 5d-2.0%

Post 10d+1.0%

Post volume2.3M

Vol ×10d2.42×

Vol ×20d2.21×

Post range8.0%